Gain Therapeutics plans Phase 2 trial of rexaceract in Parkinson's disease for Q1 2027 start
GANX•Gain Therapeutics plans to file a Phase 2 protocol for rexaceract with the FDA in coming weeks, targeting trial initiation in Q1 2027; yearlong extension results showed broadly stable motor assessments and no new safety signals.
1. Phase 2 plans
Gain Therapeutics plans to file a Phase 2 protocol for rexaceract in Parkinson's disease with the FDA in coming weeks, targeting a Q1 2027 trial start. The company disclosed long-term Phase 1b extension results showing motor assessments remained broadly stable over a year of dosing and no new safety signals emerged; results are slated for poster presentation Oct. 4-8, 2026.
